UBS/CALL/MODERNA/150.001/0.1/21.03.25 | Market Closed - Swiss Exchange 16:20:00 28/06/2024 BST | ||
| 1.19 CHF | -5.56% |
|
| Current month | -54.92% | ||
| 1 month | -60.73% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
| Date | Price | Change |
|---|---|---|
| 28/06/24 | 1.19 | -5.56% |
| 27/06/24 | 1.26 | -24.55% |
| 26/06/24 | 1.67 | -13.02% |
| 24/06/24 | 1.92 | +2.67% |
| 21/06/24 | 1.87 | -3.61% |
Delayed Quote Swiss Exchange
Last update June 28, 2024 at 04:20 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | UBS |
| TMRN4U | |
| ISIN | CH1330871976 |
| Date issued | 18/03/2024 |
| Strike | 150 $ |
| Maturity | 21/03/2025 (265 Days) |
| Parity | 10 : 1 |
| Emission price | 0.92 CHF |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | CHF |
Technical Indicators
| Highest since issue | 3.93 CHF |
|---|---|
| Lowest since issue | 0.8 CHF |
| Spread | 0.05 CHF |
| Spread % | 4.20% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
118.8
USD
Average target price
145.9
USD
Spread / Average Target
+22.82%
- Stock Market
- Warrants
- TMRN4U Warrant
